重组人促红细胞生成素治疗肿瘤相关性贫血的临床研究  

Clinical Study of Recombinant Human Erythropoietin on Tumor Related Anemia

作　　者：林长裕 何伟珊 李伟健[1] 

机构地区：[1]广东省普宁市人民医院,广东普宁515300 [2]广东省普宁市华侨医院

出　　处：《中国医学创新》2015年第14期25-27,共3页Medical Innovation of China

摘　　要：目的:探讨重组人促红细胞生成素对肿瘤相关性贫血患者的临床应用价值。方法:选取110例肿瘤相关性贫血患者为研究对象,根据随机数字表法将患者分成联合组(A组,n=60)和对照组(B组,n=50)两组。B组采用单纯化疗方案,A组采用重组人促红细胞生成素联合化疗治疗方案,对比两组患者临床治疗效果及不良反应发生情况,记录其用药前后红细胞计数(RBC)、血红蛋白水平(Hb)及血细胞比容(HCT)变化差异。结果:(1)A组显效20例,有效21例,临床治疗总有效率为68.3%,明显高于B组的48.0%,差异有统计学意义(P<0.05)。(2)治疗后,两组患者红细胞计数、血红蛋白水平及血细胞比容等指标均较治疗前明显提升,且A组增幅大于B组(P<0.05)。(3)两组患者均无严重不良反应发生,其中A组发生率为63.3%,B组为58.0%,差异无统计学意义(P>0.05)。结论:对肿瘤相关性贫血患者予以化疗联合重组人促红细胞生成素方案,疗效确切,可有效改善其贫血症状,值得临床推广。Objective：To investigate the clinical application value of recombinant human erythropoietin on the patients with tumor related anemia.Method：110 patients with malignant tumor anemia were selected as the research object,according to random digit table,they were divided into combined group （group A, n=60） and control group （group B, n=50）.The incidence of adverse reactions,clinical curative effect,record count red blood cells （RBC）,the level of hemoglobin（Hb） and hematocrit（HCT） variations of two groups before and after treatment were compared.Result：（1）20 cases of group A were markedly effective in 21 cases, clinical total effective rate was 68.3%, was obviously higher than that of groupB 48%, contrast differences were significant（P〈0.05）.（2）After the treatment, two groups of patients erythrocyte count, hemoglobin and hematocrit levels were higher than before treatment, growth in groupAwas higher than B group （P〈0.05）.（3）Two groups of patients had no serious adverse reactions occur, in A group, the incidence rate of 63.3% compared to group B 58.0%, difference was not statistically significant（P〉0.05）. Conclusion：The curative effect of chemotherapy combined with recombinant human erythropoietin on the patients with tumor related anemia element scheme is exactly, can effectively improve the symptoms of anemia, is worthy of clinical promotion.

关 键 词：重组人促红细胞生成素 肿瘤相关性贫血 安全性 

分 类 号：R730.5[医药卫生—肿瘤]